Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes

被引:21
|
作者
Wang, Shiqi [1 ,2 ,3 ]
Tan, Qian [3 ]
Hou, Yayi [1 ,2 ]
Dou, Huan [1 ,2 ]
机构
[1] Nanjing Univ, Med Sch, Div Immunol, State Key Lab Pharmaceut Biotechnol, Nanjing, Peoples R China
[2] Nanjing Univ, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China
[3] Nanjing Univ, Affiliated Hosp, Nanjing Drum Tower Hosp, Sch Med,Dept Burns & Plast Surg, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
diabetes; MDSC; recruitment; targeted therapy; diabetic complications; diabetic refractory wounds; ENDOTHELIAL GROWTH-FACTOR; REGULATORY T-CELLS; INSULIN-RESISTANCE; BONE-MARROW; ATHEROSCLEROSIS RISK; CHRONIC INFLAMMATION; TUMOR PROGRESSION; REACTIVE OXYGEN; GENE-EXPRESSION; POOR-PROGNOSIS;
D O I
10.3389/fphar.2021.798320
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetes is a syndrome characterized by hyperglycemia with or without insulin resistance. Its etiology is attributed to the combined action of genes, environment and immune cells. Myeloid-derived suppressor cell (MDSC) is a heterogeneous population of immature cells with immunosuppressive ability. In recent years, different studies have debated the quantity, activity changes and roles of MDSC in the diabetic microenvironment. However, the emerging roles of MDSC have not been fully documented with regard to their interactions with diabetes. Here, the manifestations of MDSC and their subsets are reviewed with regard to the incidence of diabetes and diabetic complications. The possible drugs targeting MDSC are discussed with regard to their potential of treating diabetes. We believe that understanding MDSC will offer opportunities to explain pathological characteristics of different diabetes. MDSC also will be used for personalized immunotherapy of diabetes.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Myeloid-derived suppressor cells in gliomas
    Gieryng, Anna
    Kaminska, Bozena
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (05): : 345 - 351
  • [32] Myeloid-Derived Suppressor Cells and Radiotherapy
    Jimenez-Cortegana, Carlos
    Galassi, Claudia
    Klapp, Vanessa
    Gabrilovich, Dmitry, I
    Galluzzi, Lorenzo
    [J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (05) : 545 - 557
  • [33] On the origin of myeloid-derived suppressor cells
    Millrud, Camilla Rydberg
    Bergenfelz, Caroline
    Leandersson, Karin
    [J]. ONCOTARGET, 2017, 8 (02) : 3649 - 3665
  • [34] Myeloid-derived suppressor cells in cancer
    Bronte, Vincenzo
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (08) : 878 - 878
  • [35] Myeloid-derived suppressor cells in glioma
    Mirghorbani, Masoud
    Van Gool, Stefaan
    Rezaei, Nima
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 1395 - 1406
  • [36] EBV and myeloid-derived suppressor cells
    Sinha, Debottam
    Khanna, Rajiv
    [J]. BLOOD, 2021, 137 (02) : 148 - 150
  • [37] History of myeloid-derived suppressor cells
    James E. Talmadge
    Dmitry I. Gabrilovich
    [J]. Nature Reviews Cancer, 2013, 13 : 739 - 752
  • [38] Myeloid-Derived Suppressor Cells in Sepsis
    Lai, Dengming
    Qin, Chaojin
    Shu, Qiang
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [39] Defining myeloid-derived suppressor cells
    Akkari, Leila
    Amit, Ido
    Bronte, Vincenzo
    Fridlender, Zvi G.
    Gabrilovich, Dmitry I.
    Ginhoux, Florent
    Hedrick, Catherine C.
    Ostrand-Rosenberg, Suzanne
    [J]. NATURE REVIEWS IMMUNOLOGY, 2024,
  • [40] Myeloid-derived Suppressor Cells in Sepsis
    van der Poll, Tom
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 196 (03) : 256 - 258